drugset
drugset / Trial / NCT05642585

A Study of Single-dose MY008211A in Healthy Adults

NCT05642585 ↗

Phase 1 Completed 63 enrolled Wuhan Createrna Science and Technology Co., Ltd
RandomizedSequentialQuadruple-blindTreatment

Summary

The trial is the first human trial. The safety, tolerability, PK and PD of MY008211A Tablets will be evaluated in healthy subjects.

Timeline

Start
2022-05-27
Primary completion
2023-06-04
Completion
2023-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject MY008211A Unknown — Oral

Indications

paroxysmal nocturnal hemoglobinuria